Dr. Strosberg on Quality of Life Findings for Lu-Dotatate in Patients with Midgut NETs

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

This preliminary analysis was part of the phase III NETTER-1 trial, which compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. The analysis focused on the global health quality of life, which is an important quality of life endpoint in any type of cancer, Strosberg says.

Patients were provided with quality of life questionnaires containing both general cancer quality of life questions and specific gastrointestinal neuroendocrine tumor questions. What the analysis found was that, on average, more patients in the Lu-Dotatate arm of the study had improvement in their quality of life. Additionally, compared to the group receiving high-dose octreotide, fewer patients had a decline in their quality of life.

Overall, these results are very encouraging, Strosberg says.

<<<

View more from the 2017 GI Cancers Symposium